Gastroesophageal Junction Adenocarcinoma Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
E
No longer available
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- (no location specified)
2022-04-06
Apr 6, 2022N
Recruiting
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8
- +27 more
- Carboplatin
- +4 more
- Anchorage, Alaska
- +451 more
2022-04-05
Apr 5, 2022N
Recruiting
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Trastuzumab Deruxtecan (T-DXd)
- Kashiwa, Chiba, JapanNational Cancer Center Hospital East
2022-04-05
Apr 5, 2022N
Recruiting
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- non-intervention
- Guangzhou, Guangdong, ChinaNanfang Hospital, Southern Medical University
2022-03-24
Mar 24, 2022I
Not yet recruiting
- Gastric Cancer
- +5 more
- IMU-131
- +2 more
- Woodville South, South Australia, AustraliaThe Queen Elizabeth Hospital
2022-03-27
Mar 27, 2022S
Recruiting
- Gastric Adenocarcinoma
- +2 more
- tucatinib
- +5 more
- Birmingham, Alabama
- +41 more
2022-04-01
Apr 1, 2022H
S
Recruiting
- Small Cell Lung Cancer
- +8 more
- ladiratuzumab vedotin
- Chandler, Arizona
- +64 more
2022-04-01
Apr 1, 2022M
Active, not recruiting
- Gastric Cardia Adenocarcinoma
- +7 more
- Carboplatin
- +10 more
- Phoenix, Arizona
- +1 more
2022-03-25
Mar 25, 2022A
Recruiting
- Gastric Cancer
- +2 more
- Evorpacept (ALX148)
- +3 more
- Anaheim, California
- +18 more
2022-04-01
Apr 1, 2022F
Recruiting
- Stomach Cancer
- +3 more
- Abbeville, France
- +37 more
2022-03-23
Mar 23, 2022A
Recruiting
- Advanced Solid Tumor
- +9 more
- Phoenix, Arizona
- +20 more
2022-03-31
Mar 31, 2022A
Recruiting
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Bemarituzumab
- +2 more
- Anchorage, Alaska
- +31 more
2022-03-23
Mar 23, 2022N
Active, not recruiting
- Esophageal Adenocarcinoma
- +6 more
- Carboplatin
- +6 more
- Birmingham, Alabama
- +633 more
2022-03-19
Mar 19, 2022E
Recruiting
- Ovarian Cancer
- +68 more
- Phoenix, Arizona
- +6 more
2022-03-21
Mar 21, 2022A
Recruiting
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Bemarituzumab
- +3 more
- Phoenix, Arizona
- +10 more
2022-03-17
Mar 17, 2022I
Terminated
- Carcinoma, Squamous Cell of Head and Neck
- +3 more
- ilixadencel
- Pembrolizumab
- Coral Gables, Florida
- +4 more
2022-03-01
Mar 1, 2022H
Recruiting
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Atezolizumab
- +3 more
- Beijing, China
- +9 more
2022-03-11
Mar 11, 2022E
Recruiting
- Urothelial Carcinoma
- +13 more
- Gilbert, Arizona
- +123 more
2022-03-08
Mar 8, 2022C
Recruiting
- Cancer of Head and Neck
- +10 more
- OncoPrism™ assay
- San Francisco, CaliforniaCurebase
2022-03-08
Mar 8, 2022G
Active, not recruiting
- Pancreatic Adenocarcinoma
- +13 more
- GB1275
- +2 more
- San Francisco, California
- +7 more
2022-02-22
Feb 22, 2022E
Completed
- Metastatic Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Ramucirumab
- +4 more
- Akashi, Japan
- +33 more
2022-02-23
Feb 23, 2022C
Withdrawn
- Esophageal Squamous Cell Carcinoma
- +2 more
- Epacadostat
- +3 more
- Duarte, California
- +2 more
2022-02-21
Feb 21, 2022M
Completed
- Gastroesophageal Junction Adenocarcinoma
- +6 more
- Carboplatin
- +4 more
- Houston, TexasM D Anderson Cancer Center
2022-02-16
Feb 16, 2022C
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
Recruiting
- Gastric Adenocarcinoma
- +2 more
- CT041 autologous CAR T-cell injection
- Physician's Choice(Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody)
- Hefei, Anhui, China
- +9 more
2022-02-13
Feb 13, 2022